Sign in

Private company

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. is a pharmaceutical preparations company.1 It is headquartered in Palo Alto, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersPalo Alto, California1
  • Business address260 Sheridan Avenue, Suite 400, Palo Alto, Ca 943062
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

On September 25, 2020, we entered into the LSAC Merger Agreement. At the effective time of the LSAC Merger, each share of Legacy Vincera Pharma Common Stock, other than any Dissenting Shares (as defined in the LSAC Merger Agreement), was canceled and the Legacy Holders received (i) 0.028545 shares of our common stock, for each share of Legacy Vincera Pharma Common Stock held by them immediately prior to the effective time of the LSAC Merger and (ii) the right to receive Earnout Shares under certain conditions following the closing of the LSAC Business Combination.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$31.5M in 2024+194% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$10.7M-$10.7M20202021: -$62.7M-$62.7M2021+485%2022: -$71.2M-$71.2M2022+14%2023: -$42.6M-$42.6M2023−40%2024: -$31.5M-$31.5M2024−26%
Net income4567-$30.1M in 2024+81% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$16.6M-$16.6M20202021: -$39.3M-$39.3M2021+136%2022: -$63.0M-$63.0M2022+60%2023: -$40.2M-$40.2M2023−36%2024: -$30.1M-$30.1M2024−25%
Fiscal year2019202020212022202320242025
Operating expenses$62.7M5$71.2M6$42.6M7$31.5M7
Operating income-$10.7M4-$62.7M5-$71.2M6-$42.6M7-$31.5M7
Interest$8.0K4$8.0K4
Income before tax-$39.3M5-$63.0M6-$40.2M7-$30.1M7
Income tax$81210
Net income-$16.6M4-$39.3M5-$63.0M6-$40.2M7-$30.1M7
Earnings per share-$2.295-$3.006-$37.727-$15.857
Earnings per share (diluted)-$2.295-$3.006-$37.727-$15.857
Shares (weighted, basic)17.2K shares521.0K shares61.1K shares71.9K shares7
Shares (weighted, diluted)17.2K shares521.0K shares61.1K shares71.9K shares7

Compare Vincerx Pharma, Inc. with another company

Corporate structure

Vincerx Pharma, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Vincerx Pharma, Inc.

  • Vincerx Pharma, Inc. Palo Alto, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Vincerx Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$07 Dec 31, 2024$256.0K7 Dec 31, 2023−100.0%
Accumulated depreciation$07 Dec 31, 2024$131.0K7 Dec 31, 2023−100.0%
Property and equipment, net$07 Dec 31, 2024$125.0K7 Dec 31, 2023−100.0%
Operating-lease assets (leased space)$07 Dec 31, 2024$2.2M7 Dec 31, 2023−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.0M7 Dec 31, 2024$12.8M7 Dec 31, 2023−61.0%
Marketable securities, current$06 Dec 31, 2023$40.8M6 Dec 31, 2022−100.0%

Leadership

Who has led Vincerx Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ahmed Hamdy Md.2020–2024

President

  1. Ahmed Hamdy Md.2020

Chief financial officer

  1. David Dobkin2020
  2. Alexander A. Seelenberger2020–2024
  3. Kevin Haas2025

Chief operating officer

  1. Michael Yehuda Rice2020
2025
Board members and other officers (21)

Former names

  • Vincera Pharma, Inc.Nov 6, 2020 to Jan 5, 20212
  • LifeSci Acquisition Corp.Dec 12, 2019 to Dec 22, 20202

Timeline

  1. Jul 7, 20258-K Ended a material agreement; Executive or director change; Other events34
  2. Apr 17, 20258-K Listing notice or transfer; Other events35
  3. Apr 11, 20258-K Ended a material agreement; Other events36
  4. Mar 18, 20258-K Entered a material agreement; Other events37
  5. Feb 28, 20258-K Ended a material agreement; Other events38
  6. Feb 18, 20258-K Other events39
  7. Feb 6, 20258-K Entered a material agreement40
  8. Jan 23, 20258-K Other events41
  9. Jan 23, 20258-K Regulation FD disclosure42
  10. Jan 21, 20258-K Entered a material agreement; Other events43
  11. Jan 16, 20258-K Ended a material agreement; Shareholder vote44
  12. Dec 27, 20248-K Entered a material agreement; Exit or restructuring costs; Executive or director change45
  13. Dec 28, 2020New chief executive Ahmed Hamdy Md. becomes CEO12

Calendar

When it reported results

  1. Nov 12, 2024Reported quarterly or annual results46
  2. Aug 8, 2024Reported quarterly or annual results47
  3. May 14, 2024Reported quarterly or annual results48
  4. Apr 25, 2024Reported quarterly or annual results49
  5. Mar 29, 2024Reported quarterly or annual results50
  6. Nov 14, 2023Reported quarterly or annual results51
  7. Aug 7, 2023Reported quarterly or annual results52
  8. May 11, 2023Reported quarterly or annual results53

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

223 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 43 major events, 66 insider forms, 26 large holders, 73 other. The latest 20:

  1. Jul 29, 2025SCHEDULE 13G/A EDGAR
  2. Jul 16, 2025DEFA14A EDGAR
  3. Jul 7, 2025DEFA14A EDGAR
  4. Jul 7, 20258-K EDGAR
  5. Jun 18, 2025DEFA14A EDGAR
  6. Jun 6, 2025DEFA14A EDGAR
  7. May 15, 202510-Q EDGAR
  8. May 15, 2025SCHEDULE 13G/A EDGAR
  9. May 12, 2025DEF 14A EDGAR
  10. May 2, 2025EFFECT EDGAR
  11. May 2, 2025EFFECT EDGAR
  12. May 2, 2025EFFECT EDGAR
  13. May 1, 2025S-8 POS EDGAR
  14. May 1, 2025S-8 POS EDGAR
  15. May 1, 2025S-8 POS EDGAR
  16. May 1, 2025S-8 POS EDGAR
  17. May 1, 2025S-8 POS EDGAR
  18. May 1, 2025POS AM EDGAR
  19. May 1, 2025POS AM EDGAR
  20. May 1, 2025POS AM EDGAR

The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

19 open-market trades by officers, directors and large owners since October 2021: 19 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 11, 2023Seelenberger Alexander A.Chief Financial OfficerBuy10,500$0.95$10.0KForm 4
Aug 10, 2023Hamdy Ahmed MDChief Executive OfficerBuy5,400$0.96$5.2KForm 4
Aug 10, 2023THOMAS TOM CSee RemarksBuy5,000$0.95$4.8KForm 4
Aug 10, 2023Izumi Raquel E.See RemarksBuy3,440$0.93$3.2KForm 4
Aug 9, 2023Hamdy Ahmed MDChief Executive OfficerBuy16,900$0.95$16.1KForm 4
Aug 9, 2023Izumi Raquel E.See RemarksBuy13,036$0.90$11.7KForm 4
Dec 14, 2022Izumi Raquel E.See RemarksBuy28,738$0.88$25.3KForm 4
Dec 14, 2022Hamdy Ahmed MDChief Executive OfficerBuy35,280$0.87$30.7KForm 4
Dec 14, 2022THOMAS TOM CSee RemarksBuy7,000$0.83$5.8KForm 4
Aug 25, 2022LOWE CHRISTOPHER P.DirectorBuy11,600$1.65$19.1KForm 4
Aug 24, 2022LOWE CHRISTOPHER P.DirectorBuy18,400$1.65$30.4KForm 4
Jun 27, 2022Izumi Raquel E.See RemarksBuy40,000$1.41$56.4KForm 4
Jun 23, 2022Hamdy Ahmed MDChief Executive OfficerBuy24,200$1.41$34.1KForm 4
Jun 9, 2022Bushnell Laura I.DirectorBuy15,000$1.91$28.6KForm 4
Dec 23, 2021Hwang SooinChief Business OfficerBuy3,000$10.00$30.0KForm 4
Dec 22, 2021THOMAS TOM CSee RemarksBuy1,000$10.23$10.2KForm 4
Dec 22, 2021Bushnell Laura I.DirectorBuy2,402$10.48$25.2KForm 4
Dec 22, 2021Seelenberger Alexander A.Chief Financial OfficerBuy2,417$10.34$25.0KForm 4
Dec 22, 2021Hamdy Ahmed MDChief Executive OfficerBuy6,450$10.02$64.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Vincerx Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVincerx Pharma, Inc.1
  • CIK0001796129
  • Employer ID (EIN)83-31974023
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address260 Sheridan Avenue, Suite 400, Palo Alto, CA 943061
  • Phone650-800-66761
  • Shares outstanding5,234,277 as of Apr 30, 20259
  • Public float$21.0M as of Jun 30, 20243
  • AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceDec 12, 20191
  • Filings371 in all: 4 (98), 8-K (62), 3 (27), 424B3 (18), 10-Q (15), SC 13G/A (15), SC 13G (14), DEFA14A (13)1
    All 42 form types

    CORRESP (11), EFFECT (10), UPLOAD (10), DEF 14A (7), 10-K (6), 424B5 (6), POS AM (5), S-8 (5), S-8 POS (5), SCHEDULE 13G/A (5), PRE 14A (3), S-1 (3), S-1/A (3), SC 13D (3), SC TO-I/A (3), 25-NSE (2), 8-K/A (2), ARS (2), PRER14A (2), S-3 (2), 10-K/A (1), 25 (1), 424B4 (1), 425 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), PREM14A (1), S-1MEF (1), S-3/A (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2025
    Quarterly report (10-Q) May 15, 2025
    Proxy statement (DEF 14A) May 12, 2025
    Latest 8-K (8-K) Jul 7, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareVINCThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 27, 2025 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Vincerx Pharma, Inc. names in Item 1A of its 10-K filed Mar 27, 2025: 66 risks under these headings, as written.3

  • Risks Related to the Proposed Business Combination
  • The Proposed Business Combination may not be consummated on the terms described in the non-binding Letter of Intent or at all.
  • Failure to consummate the Proposed Business Combination could negatively affect our business, and result in the total loss of your investment.
  • Vincerx and QumulusAI will be subject to various uncertainties while the Proposed Business Combination is pending that could adversely affect the anticipated benefits of the Proposed Business Combination.
  • We expect to incur substantial transaction costs in connection with the Proposed Business Combination.
  • Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
  • We are currently substantially dependent on the success of VIP943, our lead product candidate, and our other product candidates. If we are unable to complete development of, obtain approval for, partner, and/or commercialize these product candidates in a timely manner, our business will be harmed.
  • We are at an early stage in development efforts for our product candidates, and we may not be able to successfully develop, manufacture, complete clinical trials, partner, and/or commercialize our product candidates on a timely basis or at all.
  • Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials.
  • Interim, “topline,” and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.
  • If the market opportunity for any product candidate is smaller than we believe, our potential commercial opportunity may be adversely affected, and our business may suffer.
The other 55 risks
  • We face significant competition, and if our competitors develop and market technologies or products more rapidly or that are more effective, safer, or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
  • Clinical trials are expensive, time consuming, subject to enrollment and other delays, and may be required to continue beyond our available funding, and we cannot be certain that we will be able to raise sufficient funds to successfully complete the development, clinical trials, and commercialization of any of our product candidates.
  • If we suffer significant delays, setbacks, or negative results in, or termination of, our clinical trials, we may be unable to continue development of our product candidates, and our development costs could increase significantly. Adverse or inconclusive results from our clinical trials may substantially delay, or halt entirely, any further development of our product candidates.
  • Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such inability could have an adverse effect on our business.
  • We make use of biomarkers in certain instances, which are not scientifically validated, and our reliance on biomarker data may cause us to direct our resources inefficiently.
  • The failure to attract and retain skilled personnel could impair our drug development and business objectives.
  • We or the third parties upon whom we depend may be adversely affected by natural disasters, health epidemics, and other natural or man-made accidents or incidents, including the impact of climate change, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  • Our business and operations would be adversely affected in the event that our computer systems or those of our partners, contract research organizations, contractors, consultants, or other third parties we work with were to suffer system failures, cyberattacks, loss of data, or other security incidents, or we fail to comply with applicable data security and privacy laws, regulations, and standards.
  • Risks Related to Our Financial Position and Need for Additional Capital
  • We previously announced that we are exploring strategic alternatives and also implemented certain workforce reductions and other cost-control measures to streamline our operations and focus our resources, and there can be no assurance that such measures will achieve the intended objectives, or that they will not adversely affect our business.
  • We have incurred net losses since inception and expect to continue to incur significant net losses for the foreseeable future, and there can be no assurance we will be able to raise capital.
  • We require substantial capital to finance our operations. If we are unable to raise capital when needed, or on acceptable terms, we may be forced to significantly reduce our operations and expenses, may not be able to continue as a going concern, and may be forced to cease operations.
  • The Bayer License Agreement obligates us to make significant milestone and royalty payments, some of which would be triggered prior to any commercialization of our product candidates, and we may not be able to raise additional capital or enter into strategic alliances at levels sufficient to pay these amounts when due.
  • We may never achieve or sustain profitability.
  • Risks Related to Regulatory Approval and Other Legal Compliance Matters
  • We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to partner or commercialize our product candidates.
  • Our product candidates may cause adverse events, toxicities, or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential, or result in significant negative consequences.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of such product candidates in other jurisdictions.
  • Even if our product candidates were to receive regulatory approval, they would be subject to significant post-marketing regulatory requirements and oversight.
  • There can be no assurance that we will be able to pursue accelerated or other expedited approval of any of our product candidates, and the failure to obtain such accelerated or other expedited approval would result in a longer time period to commercialization of such product candidates, which could increase the cost of development and harm our competitive position in the marketplace.
  • We may be required to defend lawsuits or pay damages in connection with the alleged or actual violation of healthcare statutes such as fraud and abuse laws, and our corporate compliance programs cannot guarantee that we will always be in compliance with all relevant laws and regulations.
  • Our employees, agents, contractors, or collaborators may engage in misconduct or other improper activities.
  • Risks Related to Our Dependence on Third Parties
  • Our manufacturing processes are complex, and we do not have our own manufacturing capabilities and rely on third-party manufacturers for the development, clinical trials, and commercialization of any product candidate we may develop or sell.
  • If we fail to enter into and maintain successful collaborative arrangements or strategic alliances for our product candidates, our ability to develop and commercialize such product candidates will be adversely affected.
  • Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
  • Our applications for regulatory approval could be delayed or denied due to problems with studies conducted before we in-licensed the rights to some of our product candidates.
  • Due to our reliance in part on contract research organizations and other third parties to conduct clinical trials, we may be unable to directly control the timing, conduct, and expense of all aspects of our clinical trials.
  • Risks Related to Our Intellectual Property
  • If we fail to comply with our obligations under any license, collaboration, or other agreement, including the Bayer License Agreement, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.
  • Our business depends on our ability to protect our intellectual property and our proprietary technologies.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
  • The validity, scope, and enforceability of any patents that cover a biologic subject to approval by the FDA via a BLA, such as VIP943 and VIP924, can be challenged by third parties.
  • We may be involved in lawsuits to protect or enforce our patents or our licensors’ patents, which could be expensive, time consuming, and unsuccessful. Further, our issued patents or our licensors’ patents could be found invalid or unenforceable if challenged in court.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline.
  • Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
  • Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • We may be subject to claims challenging the inventorship or ownership of our licensor’s patents, our patents and other intellectual property.
  • Patent terms may not protect our competitive position on our product candidates for an adequate amount of time.
  • If we do not obtain patent term extension for our product candidates, our business may be materially harmed.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be adversely affected.
  • If we are unable to protect the confidentiality of our proprietary information, our business and competitive position would be harmed.
  • We may be subject to claims that we or our employees, agents, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of third parties.
  • We may need to license intellectual property from third parties, and such licenses may not be available on commercially reasonable terms or at all.
  • Our business depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Risks Related to Operating as a Public Company
  • If we are not able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted, which could negatively impact the liquidity and price of our common stock, our ability to complete a business combination or access the capital markets, and the confidence of investors and others.
  • As a public company, we face significant expenses and administrative burdens, which could have an adverse effect on our business, financial condition, and results of operations.
  • We are an “emerging growth company” within the meaning of the Securities Act, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our stock less attractive to investors.
  • Our failure to timely and effectively implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could have a material adverse effect on our business.
  • Any material weaknesses in or other inability to maintain effective internal control over financial reporting could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.
  • General Risk Factors
  • Our stock price has been volatile and our stock has been thinly traded, and you may not be able to sell shares of our common stock at or above the price you paid.
  • Volatility in our stock price could subject us to securities class action litigation.
  • If securities or industry analysts do not publish research or reports about us, or publish negative reports, our stock price and trading volume could decline.
  • Future sales of shares of our common stock may depress the market price of our common stock.
  • Our Certificate of Incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, or stockholders.
  • We have never paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future.

Legal proceedings

We are not currently a party to any legal proceedings, and are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition. We may from time to time become involved in legal proceedings arising in the ordinary course of business.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65